Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

BACKGROUND: Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. METHODS: Patients with primary triple negative breast cancer ≥2 cm received doxor...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:PLoS One
Main Authors: Di Cosimo, Serena, La Verde, Nicla, Moretti, Anna, Cazzaniga, Marina Elena, Generali, Daniele, Bianchi, Giulia Valeria, Mariani, Luigi, Torri, Valter, Crippa, Flavio, Paolini, Biagio, Scaperrotta, Gianfranco, De Santis, Maria Carmen, Di Nicola, Massimo, Apolone, Giovanni, Gulino, Alessandro, Tripodo, Claudio, Colombo, Mario Paolo, Folli, Secondo, de Braud, Filippo
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2019
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6685628/
https://ncbi.nlm.nih.gov/pubmed/31390375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0220644
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker